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Abstract: A successful oncolytic virus is one that selectively propagates and destroys cancerous 
tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles 
virus (MV) is one such virus that exhibits this characteristic and thus has rapidly emerged as a 
potentially useful anticancer modality. Derivatives of the Edmonston MV vaccine strain possess a 
remarkable safety record in humans. Promising results in preclinical animal models and evidence 
of biological activity in early phase trials contribute to the enthusiasm. Genetic modifications 
have enabled MV to evolve from a vaccine agent to a potential anticancer therapy. Specifically, 
alterations of the MV genome have led to improved tumor selectivity and delivery, therapeutic 
potency, and immune system modulation. In this article, we will review the advancements that 
have been made in the design and development of MV that have led to its use as a cancer therapy. 
In addition, we will discuss the evidence supporting its use, as well as the challenges associated 
with MV as a potential cancer therapeutic.
Keywords: virotherapy, measles virus, oncolytic therapy
Introduction
To minimize risk to the patient and general population, an ideal oncolytic virus should 
selectively kill tumor cells while being nonpathogenic to noncancerous tissue. The 
Edmonston strain of measles virus (MV-Edm) and its various derivatives meet these 
criteria. MV is a member of the genus Morbillivirus in the Paramyxoviridae family. 
MV is a spherical, enveloped virus that has a nonsegmented, single-stranded, negative-
sense RNA genome that comprises approximately 16,000 nucleotides, encoding six 
genes that are translated into eight viral proteins.1,2
The vast majority of MV oncolytic therapy studies utilize derivatives of the MV-
Edm strain. This strain was isolated in 1954 by John Enders and Thomas Peebles from 
a throat culture of a young boy named David Edmonston.3 Serial passaging of MV-Edm 
in human and monkey kidney cells resulted in the loss of the virus’s pathogenicity, 
allowing for the creation of the first live, attenuated MV vaccine in 1963.4 The safety 
of using MV-Edm clinically has been demonstrated over the last 50 years with over a 
billion human recipients worldwide.5 Furthermore, there has been no documentation 
of the reversion of MV-Edm back to pathogenic MV.
Three receptors that permit MV entry into human cells have been identified: 
signaling lymphocyte activation molecule, membrane cofactor protein (CD46), and 
nectin-4.6–8 CD46, a regulator of complement activation, is the preferred receptor 
for all laboratory strains of MV-Edm. This tropism was acquired following a single 
amino acid substitution at position 481, changing an asparagine to a tyrosine.9–11 
Oncolytic Virotherapy 2015:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
110
Hutzen et al
Tumor selectivity is conferred by MV-Edm’s acquired 
tropism for CD46.9 Overexpression of CD46 is frequently 
seen in human cancer cells, where it most likely serves as 
a survival mechanism to protect the transformed cells from 
complement-mediated lysis.12–14 CD46 overexpression has 
been documented in numerous cancers including brain, 
breast, cervical, colorectal, endometrial, gastrointestinal, 
hepatocellular, lung, renal and ovarian carcinomas, and has 
also been reported in hematopoietic malignancies such as 
leukemia and multiple myeloma.15–25 Although CD46 is ubiq-
uitously expressed on every nucleated cell in the human body, 
MV-Edm requires a minimum threshold of CD46 expression 
on the cell surface to initiate infection and fusion.26 The low 
CD46 densities associated with normal cells usually preclude 
MV-Edm infection and any subsequent intercellular fusion.14 
Conversely, tumor cells express high levels of CD46, thus 
making them susceptible to MV-Edm infection, which leads 
to extensive intercellular fusion (syncytia) and subsequent 
cell death.26 The dependence on receptor density to generate 
a productive virus infection allows oncolytic viruses derived 
from MV-Edm to functionally discriminate between normal 
and transformed cells.
In addition to its predilection for infecting tumor cells 
and its overall safety when administered clinically, the 
genome of MV-Edm is amenable to genetic manipula-
tion. In 1996, Radecke et al developed a reverse genetic 
system for MV rescue that allowed recombinant MV 
to be generated from cDNA ushering in a new era of 
measles-based virotherapies.14,27 Genetic manipulation of 
MV cDNA has made it possible to build upon the already 
considerable strengths of MV-Edm mentioned above by 
creating novel MV with enhanced attributes and functions. 
In the last 20 years, investigations have centered around 
creating recombinant MV that produces detectable markers 
that monitor viral infection, express transgenes that confer 
enhanced oncolytic or immune-modulatory activity, and con-
tain modifications that increase their selectivity for neoplastic 
tissue.14 In this article, we will review the advancements 
that have been made in the design and development of the 
original MV-Edm vaccine strain that have ultimately led to 
its use as a cancer therapy.
“Monitoring” oncolytic MVs
A critical component in evaluating oncolytic virus efficacy 
is the ability to monitor infection and spread. To facilitate 
its detection, recombinant MV-GFP and MV-CEA, two 
MV-Edm derivatives that encode green fluorescent protein 
(GFP) and carcinoembryonic antigen (CEA), respectively, 
were developed.28,29 Sequences coding for GFP and CEA 
were inserted into the 3′ end of MV genome before the N gene 
(Figure 1). Placement of the sequences here ensures maximal 
transcription and protein expression, thereby increasing the 
sensitivity of virus detection.30,31 MV-GFP is routinely used in 
in vitro evaluation when fluorescence microscopy techniques 
can be used to detect MV infection, whereas MV-CEA is used 
as a biomarker of in vivo infection when direct observation 
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Figure 1 Summary of modifications introduced into MV-Edm through genetic engineering.
Notes: Location of the placement of the modifications within the genome is depicted. Functional contributions of the modifications are described as well. Descriptions of 
these recombinant viruses can be found in the text.
Abbreviations: MV-Edm, Edmonston strain of measles virus; GFP, green fluorescent protein; CEA, carcinoembryonic antigen; wt P, wild-type phosphoprotein; NIS, sodium 
iodide symporter; NAP, neutrophil-activating protein; PNP, purine nucleoside phosphorylase; GM-CSF, granulocyte macrophage colony-stimulating factor; a-PD-L1, anti-
programmed death-1 ligand 1 antibody; a-CTLA-4, anti-cytotoxic T-lymphocyte antigen 4 antibody; ScFV, single chain fragment variable antibody.
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is not possible.28,31 Following MV-CEA infection of tumor 
cells, CEA, a nonimmunogenic soluble peptide with no 
biological function, is released into the blood stream.29 As 
CEA has a constant circulation half-life, measurement of 
CEA levels in the patient’s serum can therefore provide use-
ful information on the kinetics of MV infection. Important 
parameters including virus bioavailability, immune system 
involvement, and any potential dose-limiting toxicity can all 
be evaluated, making it possible to provide individualized 
medicine.29 The therapeutic potential of MV-CEA has already 
been demonstrated in multiple preclinical tumor models 
and is currently being tested in Phase I clinical trials for 
the treatment of recurrent ovarian cancer and glioblastoma 
multiforme (Table 1).32,33
 To demonstrate tumor-specific infection in vivo, MV-
NIS, a recombinant MV expressing the thyroidal sodium 
iodide symporter (NIS) gene, was constructed (Figure 1). 
NIS is a transmembrane ion channel that facilitates iodide 
transport into thyroid follicular cells.34,35 The administration 
of radioactive iodine and subsequent active uptake of iodide 
by cells can be used for imaging or ablation of the thyroid.36 
Tumors infected with MV-NIS similarly acquire the ability 
to concentrate radioiodine, allowing anatomical mapping of 
the tumor and infectivity status to be monitored with single 
photon emission computed tomography or positron emission 
tomography imaging techniques using 123I and 124I, respec-
tively, as tracers.34,37,38 Furthermore, MV-NIS therapy can also 
be combined with the β−-emitting radioiodine isotope 131I to 
enhance the therapeutic potency of the virus (see “Arming”).14 
The efficacy of MV-NIS treatment has been evaluated in 
preclinical models of multiple myeloma, ovarian cancer, 
pancreatic cancer, mesothelioma, prostate cancer, malignant 
gliomas, cancers of the head and neck, osteosarcoma, and 
medulloblastoma.34,39–46 Phase I/II clinical trials investigat-
ing MV-NIS in recurrent or refractory multiple myeloma, 
malignant pleural mesothelioma, ovarian epithelial cancer, 
and recurrent or metastatic squamous cell carcinoma of the 
head and neck are presently underway (Table 1).47–52
“Re-targeting” oncolytic MVs
Successful oncolytic viruses selectively kill cancer cells 
without causing excessive toxicity to non-neoplastic cells. 
To further assist in this outcome, recombinant MV has been 
engineered to target specific receptors overexpressed on 
tumor cells. As sequence determinants in the H gene are 
responsible for virus specificity, manipulation of the H gene 
to allow for targeted infection does not negatively impact 
subsequent virus fusion and syncytia formation mediated 
by the F protein.14 Mutations introduced in the H gene that 
ablates virus entry through the natural receptors CD46 and 
signaling lymphocyte activation molecule, combined with 
display of a tumor-specific ligand or single-chain antibody 
in the H gene, allow for the creation of retargeted MV 
(Figure 1).53–55 To ensure rescue of retargeted MV that no 
longer recognize their normal receptors, a pseudoreceptor 
STAR system was developed.56 This system utilizes Vero 
cells stably expressing a single-chain antibody against 6-His, 
which then allows the rescue of retargeted viruses that have 
been modified to express a 6-histidine tag at the N-terminus 
of the retargeted H protein.
Recombinant MV has successfully been developed to 
target multiple tumor-associated markers including the 
epidermal growth factor receptor, epidermal growth fac-
tor receptor-vIII, and interleukin-13 receptor α2 found on 
gliomas, myeloma markers CD38 and CD138, folate recep-
tor α receptor expressed in ovarian cancers, prostate stem 
cell antigen expressed by prostatic and pancreatic cancers, 
CD20-positive non-Hodgkin’s lymphoma, and Her-2/neu.56–65 
In each case, retargeted viruses retained their antitumor 
potency while restricting viral infection and replication to 
Table 1 Summary of completed, ongoing, and actively recruiting clinical trials using measles virus
Virus strain Phase Patient number Cancer type Route Response and  
(reference)
Status Trial 
identifiera
MV-CEA i 46 Ovarian iP SD (32) Completed NCT00408590
MV-CEA i 40 Glioblastoma multiforme CNS Recruiting NCT00390299
MV-NIS i/ii 73 Multiple myeloma iV 1 CR, 1 PR (48) Recruiting NCT00450814
MV-NIS ii 12 Multiple myeloma iV Recruiting NCT02192775
MV-NIS i 36 Pleural mesothelioma iP1 Recruiting NCT0153177
MV-NIS i/ii 54 Ovarian iPmsc Active NCT02068794
MV-NIS ii 134 Ovarian, fallopian, peritoneal iP SD (105) Recruiting NCT02364713
MV-NIS i 18 Head and neck iTu Recruiting NCT01846091
Note: aClinicalTrials.gov identifier.
Abbreviations: MV-CEA, MV that expresses the carcinoembryonic antigen; MV-NIS, MV that expresses the sodium iodide symporter; IP, intraperitoneal; CNS, central 
nervous system; iV, intravenous; iP1, intrapleural; iPmsc, intraperitoneal using infected mesenchymal stem cells; iTu, intratumoral; CR, complete response; PR, partial 
response; SD, stable disease.
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cells expressing the receptor. More importantly, retargeted 
strains, unlike their natural receptor-utilizing counterparts, 
displayed no off-target pathology following administration 
in a CD46 transgenic mouse model of MV toxicity.66
Although the ability to redirect MV tropism to gener-
ate more tumor-selective viruses is appealing, the utility of 
this approach remains clinically unproven. The impetus to 
reengineer MV tropism was based on the assumption that 
the ubiquitous expression of CD46 would result in MV 
infection and killing of normal cells.14 However, detailed 
studies determined that MV requires a minimum density of 
CD46 receptor density to induce cytopathic effect, and CD46 
expression levels in normal cells are below this minimum 
threshold.26 Furthermore, no dose limiting toxicities have 
been reported in the Phase I clinical trials with the CD46-
tropic MV-CEA and MV-NIS viruses that would warrant 
using an MV with altered tropism (Table 1).67 In the future, 
use of retargeted MV may be beneficial when the cellular 
CD46 expression level is insufficient to support virus-induced 
cytopathic effect.
An alternative approach to restrict viral tropism to tumor 
cells is the incorporation of microRNA target sites (miRTSs) 
into the viral genome.68,69 miRTS, which can inhibit transla-
tion, has been cloned into the 3′-untranslated region of both 
the viral fusion and hemagglutinin genes (Figure 1).68,69 Virus 
replication is controlled by differential microRNA expression 
documented in cancer cells. As numerous microRNAs are 
downregulated in cancer cells, virus replication is allowed to 
proceed, whereas the endogenous microRNA expression in 
normal cells prevents virus replication. Recombinant strains 
of MV have been engineered to contain target sites for brain-
specific microRNA-7, liver-specific microRNA-122, and 
gastrointestinal-specific microRNA-148a.68,69 In vitro and 
in vivo studies demonstrated that normal cells and tissues 
restricted MV replication. In comparison, malignant cells 
and tissues were permissive for virus replication. In addition, 
miRTS specific for microRNA-7 protected mice susceptible 
to MV infection following an intracerebral challenge.68
“Arming” oncolytic MVs
Advances in genetic engineering have allowed investigators 
to create “armed” viruses that have increased antitumor 
efficacy. Armed viruses combine the lytic potential of the 
virus with the therapeutic capacity of a transgene cloned 
into the viral genome. The most widely studied thera-
peutic transgene utilized to arm recombinant MV is NIS. 
Apart from providing a noninvasive means of imaging 
tumors, MV-NIS (described in “Monitoring”) enhances 
the efficacy of MV against radiosensitive malignancies by 
concentrating radioiodine in virus-infected cells.34 MV-NIS 
in combination with the β− particle emitting radioiodine 
isotope 131I significantly improved survival in preclini-
cal models of multiple myeloma and prostate cancer.34,43 
More recently, the combination of MV-NIS and 131I was 
found to have significant antitumor activity in orthotopic 
models of glioblastoma multiforme and medulloblastoma, 
radiosensitive brain tumors of adulthood and childhood, 
respectively.44,46
Investigators have also evaluated MV-PNP, an armed MV 
encoding the Escherichia coli purine nucleoside phosphory-
lase (PNP) gene (Figure 1).70 PNP is a prodrug convertase 
that catalyzes the prodrugs 6-methylpurine-2′-deoxyriboside 
(MeP-dR) and fludarabine (9-beta-D-arabinofuranosyl-2-
fluoroadenine 5’-monophosphate) into the highly cytotoxic 
6-methylpurine and 2-fluoroadenine, respectively.71 These 
highly diffusible products are metabolized to toxic adenosine 
triphosphate analogs, which can subsequently arrest DNA, 
RNA, and protein synthesis.71 Co-administration of MV-PNP 
and MeP-dR significantly prolonged survival in a subcuta-
neous syngeneic model of murine colon adenocarcinoma.70 
Complete tumor regression was also observed in nine out of 
ten animals when MV-PNP/MeP-dR was co-administered 
with the immunosuppressive agent cyclophosphamide.70 In 
separate studies, fludarabine increased the oncolytic efficacy 
of MV-PNP in xenograft models of Burkitt’s lymphoma and 
pancreatic cancer.62,64 Clinical trials with MV-PNP have yet 
to be formally proposed.
Another novel approach to increase the efficacy of MV-
Edm is to replace the defective P gene associated with the 
vaccine strain with a wild-type P gene (Figure 1).72 During 
vaccine development, mutations in the MV-Edm P gene 
resulted in defects in the P, C, and V proteins transcribed 
from the P gene, thus rendering these proteins incapable 
of suppressing the type I interferon (IFN) response.8,73 As a 
result, tumor cells infected with MV-Edm produce substan-
tially more IFNs than those infected with a wild-type MV, 
which can compromise viral gene expression.72 In a study by 
Haralambieva et al, the antitumor activity of a chimeric MV-
GFP virus armed with the wild-type P gene was evaluated 
in vitro and in vivo.72 The chimeric virus induced significantly 
lower levels of type I IFN than unmodified MV-GFP and 
displayed greater oncolytic potency against human multiple 
myeloma xenografts. Despite the improved efficacy, clinical 
testing of this chimeric MV-Edm has not been pursued due 
to concerns in the potential pathogenicity associated with 
the wild-type P gene.14
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“Immune-modulating” oncolytic MVs
Another strategy for improving the oncolytic potential of MV-
Edm is to construct recombinant MV that expresses a trans-
gene that stimulates the native antitumor immune response or 
alters the tumor microenvironment.74–76 MV-Edm derivatives 
have been constructed to express the immunostimulatory 
transgenes granulocyte macrophage colony-stimulating 
factor (GM-CSF) and IFN-β (Figure 1).42,77,78 GM-CSF 
potentiates many neutrophil functions including stimulation 
of phagocytosis, lysozyme release, oxidative metabolism, and 
recruitment of complement.79 IFN-β is involved in antibody 
production, natural killer and T-cell activation, and mac-
rophage function.80,81 Treatment of a mouse xenograft model 
of Burkitt’s lymphoma with a recombinant MV expressing 
the murine GM-CSF (MV-mGM-CSF) induced infiltration of 
activated neutrophils and an antitumor response.78 MV strains 
expressing the murine IFN-β (MV-mIFN-B) induced CD68-
positive immune cell filtration, decreased CD31-positive vas-
cular endothelial cells, and a significant antitumor response 
in xenograft models of human mesothelioma.42
MV-NAP, encoding a secreted form of the Helicobacter 
pylori neutrophil-activating protein (NAP), was also devel-
oped to modulate the immune system (Figure 1). NAP is a 
virulence factor involved in the pathogenesis of H. pylori 
infection and a potent modulator of proinflammatory 
cytokines.82 Treatment of xenograft models of lung and intra-
pleural metastatic breast cancer with MV-NAP significantly 
prolonged survival.83 Increased survival was mediated in part 
by the induction of a nonspecific inflammatory reaction in 
the tumor microenvironment.83
MV derivatives were recently generated expressing anti-
bodies against the immune checkpoint modulators cytotoxic 
T-lymphocyte antigen 4 (MV-aCTLA-4) and programmed 
death-1 ligand 1 (MV-aPD-L1) (Figure 1).84 CTLA-4 and 
PD-L1 are T-cell inhibitory factors that play critical roles 
in T-cell activation.85,86 Tumor cells co-opt these checkpoint 
modulators to escape cellular immunity, particularly against 
T-cells specific for tumor antigens. Results from clinical 
trials evaluating antibodies targeting CTLA-4 and PD-L1 
have been encouraging, with antibodies blocking CTLA-4 
being the first in the class of immune checkpoints to achieve 
US Food and Drug Administration approval. Recombinant 
MV expressing immune checkpoint modulators were con-
structed to restrict the toxicity associated with systemic 
antibody treatment to the tumor bed, as well as stimulate 
antitumor immunity. To evaluate the immunotherapeutic 
effects of oncolytic MV in vivo, a syngeneic model of 
malignant melanoma was established.84 MV-aCTLA-4 and 
MV-aPD-L1 treatment delayed tumor progression, while 
animals treated with MV-aPD-L1 had a significantly pro-
longed median overall survival. Both viruses were associated 
with a significant increase in CD3+ T-cells in the tumor and 
a decrease in FoxP3+ regulatory T-cells. Treatment with 
MV-aPD-L1 was associated with increased levels of CD8+ 
cytotoxic T-cells and activated IFN-γ expressing CD8+ cells, 
as well as an increased CD8/T-regulatory cell ratio. In vivo 
oncolytic efficacy of MV-aCTLA-4 and MV-aPD-L1 was 
evaluated in human melanoma xenografts.84 Tumor regression 
was observed in all treated mice, with complete remission 
achieved in 80% of the animals. Coupling the oncolytic 
potential of MV-Edm with immunotherapeutics may serve 
as novel treatment strategy.
“Immune-evading” oncolytic MVs
Due to previous vaccination or natural infection most can-
didates for measles virotherapy will have prior immunity 
to the virus, which may significantly impact the thera-
peutic efficacy.14,87,88 Circulating anti-MV antibodies and 
T-lymphocytes can rapidly neutralize an oncolytic MV. Fur-
thermore, antibody titers progressively increase following 
each successive exposure, thus making re-administration of 
MV very difficult.89 Multiple approaches to circumvent or 
modulate anti-measles immunity are being evaluated. One 
possible strategy to modulate the immune response is to 
combine MV therapy with immunosuppressive agents such 
as cyclophosphamide.14 Previous studies with oncolytic 
strains of herpes virus demonstrated a decrease in the innate 
immune response, enhanced oncolytic activity, and prolonged 
viral gene expression in tumors following cyclophosphamide 
treatment.90–92 A preclinical toxicology study with MV-NIS 
performed in immunocompetent squirrel monkeys (Saimiri 
sciureus) reported similar findings.93 Cyclophosphamide 
treatment prior to intravenous administration of MV-NIS 
resulted in a decreased humoral immune response to the virus 
and a prolongation of viral gene expression.93 Importantly, 
no significant toxicity was reported in these animals.93 
These preclinical observations have led to the inclusion 
of cyclophosphamide in a Phase I clinical trial evaluating 
MV-NIS in patients with recurrent or refractory multiple 
myeloma.47,48
A second novel strategy to circumvent the anti-measles 
immune response and improve viral delivery is to use infected 
cell carriers. In this approach, MV is delivered to the tumor 
in pre-infected cells such as monocytoid cell lines or mes-
enchymal stem cells.94,95 Since no naked virions are present, 
antibodies cannot neutralize the virus. Ideally, cell carriers 
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are permissive to MV infection, display some  capacity to 
traffic and deliver MV to tumor sites, and protect the virus 
from antibody neutralization.67 Cell carriers would also 
reduce sequestration of the virus by lung, liver, and spleen 
macrophages following systemic administration to treat dis-
seminated and hematopoietic malignancies.96,97 In a preclini-
cal study of ovarian cancer in passively immunized athymic 
mice, mesenchymal stem cells were shown to be susceptible 
to MV infection, migrate to the ovarian tumor xenograft, and 
provide a therapeutic benefit.95 Similar findings were reported 
in an orthotopic model of hepatocellular carcinoma in pas-
sively immunized SCID mice.98 These encouraging preclini-
cal results have led to the creation of a Phase I clinical trial 
evaluating patient derived mesenchymal stem cells as carriers 
of MV-NIS in recurrent ovarian cancer (Table 1).50
Clinical considerations
Before initiating clinical testing, the safety of MV-CEA 
and MV-NIS strains was extensively evaluated in mouse 
and primate models. Studies performed in a transgenic 
mouse lacking the IFN-α/β receptor and expressing the 
human CD46 receptor in a tissue-specific pattern similar 
to humans (Ifnarko CD46 GE), demonstrated no toxicity 
following intraperitoneal, intravenous, or CNS delivery of 
the virus.66,99,100 Subsequent toxicology studies in measles-
susceptible primates also demonstrated MV-NIS safety fol-
lowing CNS delivery in rhesus macaques (Macaca mulatta)101 
and intravenous delivery in cynomolgus monkeys (Saimiri 
sciureus).93
The safety and maximum tolerated dose of MV-CEA and 
MV-NIS are currently being evaluated in numerous Phase I 
clinical trials (Table 1).33,47–52 While data from many of these 
trials are still forthcoming, there have been no reports of dose-
limiting toxicity following administration of intraperitoneal 
doses up to 109 TCID
50
, intravenous doses up to 1011 TCID
50
, 
and CNS delivery of doses up to 107 TCID
50
. Results from 
the completed dose escalation trial involving intraperitoneal 
delivery of MV-CEA (103–109 TCID
50
) demonstrated no 
dose-limiting toxicity or virus induced immunosuppression.32 
Serum CEA levels, a marker of virus replication, were 
observed in patients receiving the highest dose (109 TCID
50
). 
Significant decreases in cancer antigen-125 levels were 
observed in five patients, and median survival of patients in 
the trial (12.15 months) was double the historical expected 
median survival in this patient population (6 months).102 
Based upon these results, a Phase I/II trial evaluating intra-
peritoneal administration of MV-NIS in treatment-resistant 
ovarian cancer was performed (Table 1).103 No dose-limiting 
toxicity was observed with MV-NIS doses up to 109 TCID
50.
 
125I uptake was detected in the tumors of three patients indi-
cating virus infection, and the overall median survival of 
26.5 months compared favorably to studies evaluating novel 
therapeutics in this patient population (6–12 months).103 
Interestingly, post-treatment evaluation showed an increase 
in IGFBP2 and Frα-specific effector T-cells, indicating a Th1 
response against the ovarian cancer cells.103
Finally, a recent report from a clinical trial investigating 
MV-NIS in recurrent drug-refractory multiple myeloma 
builds upon the encouraging results observed in ovarian 
cancer (Table 1).48 In the trial, two patients with multiple 
plasmacytomas responded to therapy following intrave-
nous delivery of MV-NIS at a dose of 1011 TCID50, with 
one patient experiencing durable complete remission at 
all disease sites.48 As MV-NIS infected cells express NIS 
and therefore concentrate iodine, single photon emission 
computed tomography was able to confirm tumor-specific 
infection following 123I administration. In the future, MV-
NIS could be combined with high-energy beta-emitting 131I 
to increase the bystander effect surrounding infected cells. 
It should be noted that two factors may have contributed 
to the favorable response to therapy observed in these two 
patients. First, both patients had low pretreatment serum 
titers of anti-measles antibodies. Second, a very high dose 
of virus was administered. Previous experience in the ovar-
ian cancer trials also suggested a dose-dependent response 
to therapy.32,103
Advantages and disadvantages  
of oncolytic MVs
There is an ever-growing list of oncolytic viruses in preclini-
cal and clinical testing. Although there are reviews describ-
ing the advantages and disadvantages associated with these 
viruses, there is virtually no information comparing their 
head-to-head efficacy. MVs offer numerous advantages 
when deciding to include oncolytic viruses as part of the 
therapeutic approach. As discussed in previous sections, 
the excellent safety profile associated with MV-Edm strains 
makes it an attractive candidate for oncolytic virotherapy 
compared with other oncolytic viruses not used as vaccine 
agents.5 In contrast to the oncolytic DNA genome containing 
adenoviruses (Ads) and herpes simplex viruses (HSVs), MV 
with its RNA genome replicates in the cytoplasm of infected 
cells thus eliminating the possibility of insertional DNA 
mutagenesis. Similar to polioviruses and vaccinia viruses 
(VVs), MV has been genetically manipulated to select for 
preferential replication in cancer cells. In contrast, Ad, HSV, 
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and vesicular stomatitis viruses (VSVs) have been genetically 
engineered with mutations or deletions in genes required for 
replication in normal but not cancer cells. There are multiple 
mechanisms by which oncolytic viruses lead to the death of 
tumor cells. While many oncolytic viruses cause tumor death 
via direct cell lyses, including MV, Ad, and HSV, the ability 
of MV to form syncytia provides an additional mechanism 
of killing that many other oncolytic viruses do not possess.104 
Expression of viral hemagglutinin and fusion proteins in MV 
infected cells interacts with CD46 expressed by noninfected 
neighboring cells thus creating a bystander effect.14 Recently 
multiple oncolytic viruses (MV, Ad, VV, and HSV) have been 
demonstrated to induce antitumor immunity.105 In this pro-
cess, local infection induces inflammation leading to immune 
stimulation and recruitment of immune cells. Cellular debris 
generated by oncolysis is taken up by antigen-presenting 
cells. Tumor antigens can then trigger cellular or antibody-
mediated immune responses.105
While MV offer many advantages compared with other 
oncolytic viruses when deciding to conduct oncolytic 
virotherapy, there are disadvantages associated with MV. 
Although immunization has demonstrated the safety of 
MV-Edm administration and provides a safety barrier for 
subsequent exposure, serum neutralizing antibodies can 
potentially compromise oncolytic MV efficacy. This is 
extremely important when attempting to treat metastatic 
tumors where intravenous delivery of oncolytic viruses is 
necessary. In contrast, VV and VSV are two oncolytic viruses 
that have the potential to exhibit efficacy when delivered 
intravenously.106,107
Conclusion and future directions
MV-Edm derivatives are a promising experimental approach 
to the treatment of cancer as they have demonstrated sig-
nificant antitumor activity in multiple preclinical models. 
Furthermore, results from completed clinical trials dem-
onstrate their safety and show early evidence of biologic 
activity in humans. Numerous genetic advancements 
have been made in the design and development of MV-
Edm derivatives. These enhancements have attempted to 
increase their safety, potency, and ability to be monitored. 
Recombinant strains targeting tumor-specific markers, or 
containing microRNA recognition sites, were designed to 
restrict virus replication to tumor cells, therefore leaving 
normal cells unharmed. MV-Edm derivatives that express 
the E. coli PNP gene, contain the P gene from the wild-type 
virus, or express NIS have been constructed to increase 
virus CPE. Furthermore, CEA and NIS reporter genes have 
made  real-time in vivo monitoring possible. There has been 
a recent impetus to construct MV-Edm derivatives that 
either evade the systemic immune response via infected cell 
carriers or illicit an antitumor immune response. Results 
regarding the safety and efficacy of MV therapy from 
ongoing clinical trials, coupled with continual evolution of 
MV-Edm derivatives, will help guide future development 
strategies, leading to a new generation of safer and more 
effective oncolytic MV.
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